Activist Investor Demands Exelixis Cut R&D Spending And Learn From Peers

CEO Pushes Back On R&D Spending Cut Calls

The mid-sized company is under siege from hedge fund Farallon and faces a fight over its R&D strategy to follow aging blockbuster Cabometyx.

Stock Index close up
The activist investors insist that greater focus on R&D spending and shareholder return will be good for business

Exelixis is facing renewed demands for change from activist investor Farallon Capital Management, which wants the mid-sized pharma company to slash its R&D spending and learn from peers on how to focus its pipeline.

The hedge fund holds 7.2% of the outstanding shares of Exelixis, making it the largest active shareholder, and has been...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category